National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure

Abstract

BackgroundDose reduction of biologics for psoriasis is applied in daily practice, although guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent application of dose reduction.ObjectiveTo achieve consensus on criteria for biologic dose reduction in psoriasis patients with stable and low disease activity.MethodsAn online Delphi procedure (eDelphi) was conducted. Dutch dermatologists were invited to participate in a maximum of 3 voting rounds. Proposed statements were selected based on literature review and included criteria for the application of dose reduction and dosing schedules. Biologic dose reduction was defined as ‘application of injection interval prolongation’. Proposed statements were rated using a 9-point Likert scale; consensus was reached when ≥70% of all voters rated ‘agree’ (7–9) and <15% rated ‘disagree’ (1–3).ResultsA total of 27 dermatologists participated and reached a consensus on 15 recommendations over 2 voting rounds. Agreed statements included criteria for dose reduction eligibility, criteria for dose reduction (dis)continuation, and dosing schedules for adalimumab, etanercept, and ustekinumab. Based on the eDelphi outcomes, an algorithm fit for implementation in current practice was developed.ConclusionsRecommendations of this national consensus process can guide clinicians, and consequently their patients, toward consistent application of biologic dose reduction.